诺瓦瓦克斯医药 (NVAX.O)

+ 收藏

现金流量表(诺瓦瓦克斯医药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2023年三季报2023年中报2023年一季报2022年年报2022年三季报2022年中报2022年一季报
起始日期 2023-01-012023-01-012023-01-012022-01-012022-01-012022-01-012022-01-01
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
报表年结日 1231123112311231123112311231
原始币种 美元美元美元美元美元美元美元
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后
经营活动产生的现金流量:
 净利润(元) -366,673,000.00-235,897,000.00-293,905,000.00-657,939,000.00-475,690,000.00-307,077,000.00203,408,000.00
 折旧及摊销(元) 30,431,000.0019,110,000.009,043,000.0029,054,000.0021,832,000.0013,485,000.006,765,000.00
 基于股票的补偿费(元) 69,699,000.0048,939,000.0028,647,000.00130,300,000.00102,525,000.0070,981,000.0032,933,000.00
 减值及拨备(元) 59,614,000.0041,627,000.0012,490,000.00447,597,000.00358,075,000.00155,662,000.00-
 经营业务调整其他项目(元) -3,015,000.00-89,000.00-1,252,000.00-3,799,000.0015,128,000.00-3,933,000.00848,000.00
 存货的减少(增加)(元) -82,542,000.00-19,361,000.00-9,222,000.00-477,801,000.00-426,466,000.00-403,725,000.00-99,557,000.00
 应收账款及票据减少(增加)(元) -34,418,000.00-266,482,000.0018,430,000.00249,166,000.00171,325,000.00112,845,000.00-56,016,000.00
 应付账款及票据增加(减少)(元) -349,261,000.00-443,238,000.00-230,099,000.00913,399,000.0090,418,000.00179,158,000.00-115,500,000.00
 递延收入(元) 138,979,000.00357,860,000.00140,275,000.00-1,045,914,000.00-155,268,000.00-76,809,000.00-61,391,000.00
 经营活动产生的现金流量净额(元) -537,186,000.00-497,531,000.00-325,593,000.00-415,937,000.00-298,121,000.00-259,413,000.00-88,510,000.00
投资活动产生的现金流量:
 购买固定资产支付的现金(元) -44,932,000.00-26,774,000.00-19,801,000.00-89,056,000.00-66,033,000.00-41,402,000.00-16,826,000.00
 购买无形资产及其他资产支付的现金(元) -4,796,000.00-4,563,000.00-3,757,000.00-3,929,000.00-4,888,000.00--
 投资活动产生的现金流量净额(元) -49,728,000.00-31,337,000.00-23,558,000.00-92,985,000.00-70,921,000.00-41,402,000.00-16,826,000.00
融资活动产生的现金流量:
 发行股份(元) 256,995,000.0061,986,000.00-249,230,000.00179,385,000.00179,385,000.00179,385,000.00
 行使股票期权所得(元) 699,000.00345,000.00543,000.00-639,000.0067,000.001,050,000.001,318,000.00
 贷款收益(元) -325,000,000.00-325,000,000.00-325,000,000.00175,250,000.00---
 发行费用相关(元) -3,591,000.00-3,591,000.00-3,591,000.00-5,258,000.00---
 其他筹资活动产生的现金流量净额(元) -----45,904,000.00--
 筹资业务其他项目(元) -25,026,000.00-26,784,000.00-26,331,000.00-93,595,000.00--15,911,000.00-20,838,000.00
 融资活动产生的现金流量净额(元) -95,923,000.00-293,044,000.00-354,379,000.00324,988,000.00133,548,000.00164,524,000.00159,865,000.00
汇率变动影响(元) 355,000.00-8,992,000.00-8,372,000.004,520,000.00257,000.00-4,453,000.001,312,000.00
现金及现金等价物期初余额(元) 1,348,845,000.001,348,845,000.001,348,845,000.001,528,259,000.001,528,259,000.001,528,259,000.001,528,259,000.00
现金及现金等价物增加(减少)额(元) -682,482,000.00-830,904,000.00-711,902,000.00-179,414,000.00-235,237,000.00-140,744,000.0055,841,000.00
现金及现金等价物期末余额(元) 666,363,000.00517,941,000.00636,943,000.001,348,845,000.001,293,022,000.001,387,515,000.001,584,100,000.00
利息支付(元) -----8,604,000.006,654,000.00
所得税支付(元) 128,000.00128,000.00-17,980,000.0017,843,000.0017,778,000.0015,451,000.00
补充资料其他项目(元) 110,804,000.0023,871,000.0017,413,000.00127,555,000.00147,506,000.00--
非现金活动(元) -----87,256,000.0074,226,000.00
公告日期 2023-11-092023-08-082023-05-092023-02-282022-11-092022-08-092022-05-10
会计准则 美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则
审计意见
核数师

前瞻产业研究院